SI2193133T1 - Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze - Google Patents

Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze

Info

Publication number
SI2193133T1
SI2193133T1 SI200831527T SI200831527T SI2193133T1 SI 2193133 T1 SI2193133 T1 SI 2193133T1 SI 200831527 T SI200831527 T SI 200831527T SI 200831527 T SI200831527 T SI 200831527T SI 2193133 T1 SI2193133 T1 SI 2193133T1
Authority
SI
Slovenia
Prior art keywords
imidazolothiadiazoles
protein kinase
kinase inhibitors
inhibitors
protein
Prior art date
Application number
SI200831527T
Other languages
English (en)
Slovenian (sl)
Inventor
Paolo Pevarello
Collazo Ana Maria Garcia
Garcia Ana Belen Garcia
Original Assignee
Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii filed Critical Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii
Publication of SI2193133T1 publication Critical patent/SI2193133T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200831527T 2007-09-27 2008-09-29 Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze SI2193133T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07381066 2007-09-27
PCT/GB2008/003287 WO2009040552A2 (en) 2007-09-27 2008-09-29 Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof
EP08806437.3A EP2193133B1 (en) 2007-09-27 2008-09-29 Imidazolothiadiazoles for use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
SI2193133T1 true SI2193133T1 (sl) 2015-12-31

Family

ID=39092755

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831527T SI2193133T1 (sl) 2007-09-27 2008-09-29 Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze

Country Status (13)

Country Link
US (1) US8563550B2 (enExample)
EP (1) EP2193133B1 (enExample)
JP (1) JP5410431B2 (enExample)
CN (1) CN101878219B (enExample)
CY (1) CY1116882T1 (enExample)
DK (1) DK2193133T3 (enExample)
ES (1) ES2548768T3 (enExample)
HR (1) HRP20151128T1 (enExample)
HU (1) HUE025976T2 (enExample)
PL (1) PL2193133T3 (enExample)
PT (1) PT2193133E (enExample)
SI (1) SI2193133T1 (enExample)
WO (1) WO2009040552A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
SI2193133T1 (sl) 2007-09-27 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
AU2009275544B2 (en) * 2008-07-29 2013-09-12 Merck Patent Gmbh Imidazothiadiazoles derivatives
SI2414369T1 (sl) * 2009-04-02 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Derivati imidazo(2,1-b)(1,3,4)tiadiazola
FR2945289A1 (fr) * 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
WO2011036461A1 (en) 2009-09-24 2011-03-31 Centro Nacional De Investigaciones Oncόlogicas (Cnio) Fused imidazo [3, 2 - d] pyrazines as pi3 kinase inhibitors
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2011101644A1 (en) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Triazolo [4, 5 - b] pyridin derivatives
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020217A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020227A1 (en) 2010-08-11 2012-02-16 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
KR101953210B1 (ko) 2011-05-19 2019-02-28 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 단백질 키나아제 억제제로서의 대환식 화합물
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
EP2671885A1 (en) * 2012-06-05 2013-12-11 Ares Trading S.A. Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
EP2682395A1 (en) 2012-07-04 2014-01-08 Laboratorios Del. Dr. Esteve, S.A. Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
WO2014015167A2 (en) * 2012-07-18 2014-01-23 University Of Notre Dame Du Lac 5,5-heteroaromatic anti-infective compounds
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
US20190119300A1 (en) * 2016-04-18 2019-04-25 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CA3104054A1 (en) 2018-08-21 2020-02-27 Kyorin Pharmaceutical Co., Ltd. Bicyclic heteroaromatic ring derivative
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
BR112022007404A2 (pt) * 2019-10-21 2022-07-05 Novartis Ag Compostos e composições para o tratamento de doenças parasíticas
WO2023093700A1 (zh) * 2021-11-29 2023-06-01 中国海洋大学 咪唑并噻唑衍生物及其制备方法与应用
CN114195736B (zh) * 2021-12-30 2023-08-04 浙江闰土染料有限公司 2-氨基-5-溴-1,3,4-噻二唑的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464259A (en) * 1975-10-03 1977-02-09 Pfizer Ltd Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
US4444770A (en) 1980-05-29 1984-04-24 Bayer Aktiengesellschaft New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use
DE3208437A1 (de) 1982-03-09 1983-09-15 Bayer Ag, 5090 Leverkusen Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
IT1269176B (it) 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
WO1997011075A1 (en) 1995-09-22 1997-03-27 Takeda Chemical Industries, Ltd. Triazole compounds, their production and use
JP2004505983A (ja) 2000-08-09 2004-02-26 アグーロン　ファーマシューティカルズ，インコーポレイテッド ピラゾール−チアゾール化合物、これらを含む医薬組成物、およびサイクリン依存性キナーゼの阻害のためのこれらの使用方法
CA2364985A1 (en) * 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
ATE473980T1 (de) 2002-12-18 2010-07-15 Vertex Pharma Triazolopyridazine als proteinkinase-inhibitoren
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1636242A1 (en) * 2003-06-13 2006-03-22 Aegera Therapeutics Inc. Acylated imidazo (2,1-b) -1,3,4,-thiadia zole-2-sulfonamides, and uses thereof
CA2527903A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics, Inc. Imidazo[2,1-b]-1,3,4-thiadiazole sulfoxides and sulfones
EP2308870A3 (en) 2005-06-01 2011-10-19 UCB Pharma S.A. 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US7750000B2 (en) 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
CA2584745A1 (en) * 2006-04-13 2007-10-13 Aegera Therapeutics Inc. Use of imidazo(2,1-b) -1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain
US20070267288A1 (en) 2006-05-21 2007-11-22 Steven Allen Carlson Systems and methods for hydrogen storage and generation
CN101037445A (zh) 2007-04-14 2007-09-19 西北师范大学 一种具有潜在生物活性的咪唑并[2，1－b]－1，3，4－噻二唑衍生物及其合成方法
KR20100019489A (ko) 2007-05-09 2010-02-18 노파르티스 아게 Ｐｉ３ｋ 지질 키나제 억제제로서의 치환된 이미다조피리다진
CN101678014B (zh) 2007-05-21 2012-12-12 Sgx药品公司 杂环激酶调节剂
SI2193133T1 (sl) 2007-09-27 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
AU2009275544B2 (en) 2008-07-29 2013-09-12 Merck Patent Gmbh Imidazothiadiazoles derivatives

Also Published As

Publication number Publication date
WO2009040552A2 (en) 2009-04-02
HUE025976T2 (en) 2016-05-30
US8563550B2 (en) 2013-10-22
PT2193133E (pt) 2015-10-22
EP2193133B1 (en) 2015-08-19
ES2548768T3 (es) 2015-10-20
EP2193133A2 (en) 2010-06-09
US20110190289A1 (en) 2011-08-04
JP2010540508A (ja) 2010-12-24
CN101878219A (zh) 2010-11-03
CY1116882T1 (el) 2017-04-05
PL2193133T3 (pl) 2016-01-29
WO2009040552A3 (en) 2009-05-22
CN101878219B (zh) 2014-04-02
JP5410431B2 (ja) 2014-02-05
DK2193133T3 (en) 2015-10-05
HRP20151128T1 (hr) 2015-11-20

Similar Documents

Publication Publication Date Title
HUS1900014I1 (hu) Proteinkináz inhibitorok
PL2193133T3 (pl) Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej
IL206416A0 (en) Benzofuropyrimidinones as protein kinase inhibitors
EP2200436A4 (en) SUBSTITUTED PYRIMIDINYLAMINE AS PROTEIN KINASENHEMMER
IL210073A0 (en) Protein kinase inhibitors
IL210069A0 (en) Protein kinase inhibitors
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
PL2610256T3 (pl) Pochodne pirymidyny jako inhibitory kinaz białkowych
IL198487A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
IL198398A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
ZA201102423B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
EP1993539A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
IL209729A0 (en) Novel phenylpyrazinones as kinase inhibitors
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
EP2336123A4 (en) HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE
EP1993535A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
EP1993537A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
EP1993536A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
EP1996191A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
IL197981A0 (en) Kinase inhibitors
EP1993538A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
GB0715470D0 (en) IKK- serine-threonine protein kinase inhibitors